Management of portal hypertension in children

Curr Gastroenterol Rep. 2011 Feb;13(1):10-6. doi: 10.1007/s11894-010-0151-y.

Abstract

Management of portal hypertension in children has evolved over the past several decades. Portal hypertension can result from intrahepatic or extrahepatic causes. Management should be tailored to the child based on the etiology of the portal hypertension and on the functionality of the liver. The most serious complication of portal hypertension is gastroesophageal variceal bleeding, which has a mortality of up to 30%. Initial treatment of bleeding focuses on stabilizing the patient. Further treatment measures may include endoscopic, medical, or surgical interventions as appropriate for the child, depending on the cause of the portal hypertension. β-Blockers have not been proven to effectively prevent primary or secondary variceal bleeding in children. Sclerotherapy and variceal band ligation can be used to stop active bleeding and can prevent bleeding from occurring. Transjugular intrahepatic portosystemic shunts and surgical shunts may be reserved for those who are not candidates for transplant or have refractory bleeding despite medical or endoscopic treatment.

MeSH terms

  • Acute Disease
  • Adrenergic beta-Antagonists / therapeutic use
  • Child
  • Endoscopy, Gastrointestinal
  • Esophageal and Gastric Varices / diagnosis
  • Esophageal and Gastric Varices / etiology
  • Esophageal and Gastric Varices / prevention & control
  • Esophageal and Gastric Varices / therapy*
  • Gastrointestinal Hemorrhage / diagnosis
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / prevention & control
  • Gastrointestinal Hemorrhage / therapy*
  • Humans
  • Hypertension, Portal / diagnosis
  • Hypertension, Portal / physiopathology
  • Hypertension, Portal / therapy*
  • Ligation
  • Portasystemic Shunt, Surgical
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Sclerotherapy
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Adrenergic beta-Antagonists
  • Vasoconstrictor Agents